Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain.
Le Hingrat Q, Collin G, Lê M, Peytavin G, Visseaux B, Bertine M, Tubiana R, Karmochkine M, Valin N, Collin F, Lemaignen A, Bernard L, Damond F, Matheron S, Descamps D, Charpentier C; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) CO5 HIV-2 Cohort. Le Hingrat Q, et al. Among authors: karmochkine m. Clin Infect Dis. 2019 Aug 1;69(4):657-667. doi: 10.1093/cid/ciy940. Clin Infect Dis. 2019. PMID: 30383215
Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
Descamps D, Peytavin G, Visseaux B, Tubiana R, Damond F, Campa P, Charpentier C, Khuong-Josses MA, Duvivier C, Karmochkine M, Lukiana T, Matheron S. Descamps D, et al. Among authors: karmochkine m. Clin Infect Dis. 2015 May 15;60(10):1521-7. doi: 10.1093/cid/civ124. Epub 2015 Feb 17. Clin Infect Dis. 2015. PMID: 25690598
Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.
Charpentier C, Roquebert B, Delelis O, Larrouy L, Matheron S, Tubiana R, Karmochkine M, Duval X, Chêne G, Storto A, Collin G, Bénard A, Damond F, Mouscadet JF, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2). Charpentier C, et al. Among authors: karmochkine m. Antimicrob Agents Chemother. 2011 Mar;55(3):1293-5. doi: 10.1128/AAC.00942-10. Epub 2010 Dec 28. Antimicrob Agents Chemother. 2011. PMID: 21189351 Free PMC article.
Minority resistant variants are also present in HIV-2-infected antiretroviral-naive patients.
Storto A, Visseaux B, Bertine M, Le Hingrat Q, Collin G, Damond F, Khuong MA, Blum L, Tubiana R, Karmochkine M, Cazanave C, Matheron S, Descamps D, Charpentier C; ANRS HIV-2 CO5 Cohort. Storto A, et al. Among authors: karmochkine m. J Antimicrob Chemother. 2018 May 1;73(5):1173-1176. doi: 10.1093/jac/dkx530. J Antimicrob Chemother. 2018. PMID: 29415189
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bénard A, Campa P, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2). Roquebert B, et al. J Antimicrob Chemother. 2008 Nov;62(5):914-20. doi: 10.1093/jac/dkn335. Epub 2008 Aug 20. J Antimicrob Chemother. 2008. PMID: 18718922
121 results